P
ancreatic cancer is a promising target for new treatment strategies despite incremental gains through earlier diagnosis and improved treatment options. Even with these improvements, the overall 5-year survival rate remains below 10%. 1 Thus, the genetic modification of human pancreatic tumor cells is critical for experimental and clinical investigations. Retroviral vectors derived from Moloney murine leukemia virus (MLV) have been extensively engineered as vehicles for transferring potentially therapeutic genes to a variety of human cell types. These vectors integrate efficiently into mitotically active cells, mediating stable gene delivery and transfer, as well as provide adequate expression of the gene(s) of interest. 2 An important consideration in the design of virions for the optimal infection of human cells is the type of viral envelope glycoprotein present within the membrane of vector virions. This protein binds to specific cell surface receptors and is the primary determinant of the range of cells that can be transduced by the recombinant vector. 3 Recombinant retroviral vectors free of replication-competent retrovirus can be generated either transiently in sufficient quantities by cotransfection of 293T cells with expression vectors containing the appropriate cis-acting packaging functions (retroviral backbone with transcriptional elements and gene(s) of interest) and trans-acting packaging functions (gag, pol, and a specific envelope glycoprotein), 4 or by engineering stable producer cell lines that package retroviruses using specific glycoprotein envelopes from other viruses. The process of using various glycoprotein envelopes to package recombinant retroviruses, referred to as pseudotyping, includes amphotropic MLV (MLV-A), 5, 6 xenotropic MLV, 7 gibbon ape leukemia virus, 8 cat endogenous virus (CEV) RD114, 9 and the rhabdovirus vesicular stomatitis virus G (VSV-G). 10 Naturally occurring retroviruses have evolved to use many different receptors for cell entry that have diverse normal functions in cells, including transport of various solutes, immune recognition, and signaling. 11, 12 Presently, Ͼ10 additional retroviral receptors have been identified and cloned. 3, 13 The retroviral vectors currently used in most human gene therapy protocols have used MLV-A.
14 Ram-1 (also known as Pit1 and Pit2), the MLV-A receptor, 15, 16 and RDR, the CEV RD114 receptor, belong to a family of related but distinct sodiumdependent phosphate transport and neutral amino acid receptors, respectively. 17, 18 In addition, retroviral vectors can be generated that contain the VSV-G glycoprotein from VSV within the viral membrane. These retroviruses use ubiquitous phosphotidylserines as receptors that are expressed in a variety of mammalian and non-mammalian cells. 19 -22 Unfortunately, the generation of VSV-G-pseudotyped retroviral virions from stable producer cell lines has been problematic due to the toxicity of VSV-G in most mammalian cells. 10, 23 Until recently, VSV-G-pseudotyped retroviral vectors involved the use of transient transfection techniques in specific cell lines to express the VSV-G protein, with the limitation of insufficient titers to conduct large experiments. This problem has been overcome by the generation of stable retroviral packaging cell lines with the VSV-G protein under inducible expression using the tet R /VP16 transactivator and tet O minimal promoter system. 24, 25 The introduction of the herpes simplex virus-1 (HSV-1) thymidine kinase (TK) gene into tumor cells is a promising strategy designed to create artificial sensitivity to the prodrug ganciclovir (GCV). In contrast to normal cellular TKs, HSV-1 TK has the ability to phosphorylate GCV. 26 Upon phosphorylation, GCVmonophosphate is further phosphorylated by other cellular kinases to GCV-triphosphate, which is incorporated into elongating DNA chains that terminate DNA synthesis and cause cell death. 27, 28 Currently, the use of HSV-1 TK is being evaluated for the treatment of human brain tumors as well as for other human cancers.
14,29 A variety of mutant HSV-1 TK genes have been generated with increased specificity for the phosphorylation of GCV with a possible enhancement of tumor cell killing without increased toxicity. 30 However, resistance to GCV-mediated cell death has been reported in HSV-1 TK-modified tumor cells and has been attributed to several mechanisms. One of the mechanisms involved loss or deletion of portions of the HSV-1 TK gene in resistant cells. 31 In addition, HSV-1 TK-positive cells are capable of transferring the toxic GCV-triphosphate via gap junctions to adjacent gene-unmodified cells and promoting cell death. 32, 33 Another mechanism of resistance involves the lack of transfer of sufficient amounts of toxic GCV-triphosphate to neighboring cells due to a lack of proper intercellular communication via desmosomes or gap junctions. 34 Little is known concerning the level of retroviral receptor expression on human pancreatic tumor cell types. The expression of envelope receptors on different target cell populations seems to be variable, and it is likely that retroviral vectors possessing particular viral glycoprotein envelopes possess limited proficiency for transducing specific cell types. 35 In addition, others have shown that Ram-1 and other envelope receptors have different patterns of tissue expression. 17 Interestingly, we observed that 4070A-pseudotyped retroviral vectors poorly infected human pancreatic cell lines and examined whether another envelope glycoprotein may possess better binding capabilities and hence mediate better delivery and expression of genes of interest. In this report, we have pseudotyped several MLV-based retroviral vectors containing either the gene for the humanized enhanced green fluorescent protein (hEGFP) or one of two HSV-TK genes (wild-type (WT) or mutant no. 30) with glycoprotein envelopes derived from MLV-A (strain 4070A), CEV RD114, or VSV-G. We have demonstrated that VSV-G-pseudotyped retroviral viral vectors not only infected a greater number of cells but delivered more provector genomes, leading to enhanced gene expression and to a better therapeutic effectiveness of HSV-TK-phosphorylated substrates for both cytotoxicity involving HSV-TK-positive cells and bystander killing. In addition, we have shown that sensitivity to GCV as well as bystander killing could be enhanced when using the HSV-TK 30 variant instead of the WT gene in an in vivo setting. These results show that the choice of glycoprotein envelope as well as the potency of a particular suicide gene were therapeutically additive and can increase the number of HSV-TKpositive cells and sensitivity toward GCV in human pancreatic tumors cells for prodrug gene therapy.
MATERIALS AND METHODS

Cell lines
293T cells (CRL 1573; American Type Culture Collection (ATCC), Manassas, Va) and NIH 3T3 cells (CRL 1658; ATCC) were grown in complete Dulbecco's modified Eagle's medium (DMEM) with 4500 mg/L glucose (Life Technologies, Eggenstein, Germany) containing 10% fetal calf sera (Hyclone Laboratories, Logan, Utah) supplemented with 2 mM glutamine, 1 mM sodium pyruvate, and 1ϫ nonessential amino acids (Life Technologies). FLYA13 (no. 95091901; European Collection of Cell Cultures (ECACC), Salisbury, UK; expressing the MLV envelope, strain 4070A) and FLYRD18 (no. 95091902; ECACC: expressing the CEV RD114 envelope) retroviral packaging cell lines were grown in complete DMEM supplemented with blastocidin (4 mg/mL) and phleomycin (10 mg/mL). 9 The 293 GPG retroviral packaging cell line expressing VSV-G (a gift of Dr. Paul Robbins, University of Pittsburgh, Pittsburgh, Penn) was also grown in complete DMEM supplemented with tetracycline (1 mg/mL), puromycin (2 mg/mL), and G418 (300 mg/mL). 25 The human pancreatic tumor cell lines Panc89 (also referred to as T3 M4) 36 and Colo357 37 have been described previously; PancTuI was kindly provided by Dr. M. von Bülow (University Hospital, Mainz, Germany). These cell lines were grown in RPMI 1640 medium containing 10% fetal calf sera (Hyclone Laboratories) supple-mented with 25 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid, 2 mM glutamine, 1 mM sodium pyruvate, and 1ϫ nonessential amino acids (Life Technologies). All cell lines were maintained in a 37°C humidified incubator containing 7.5% CO 2 /92.5% air.
Plasmids and construction of dicistronic retroviral vectors
The retroviral backbone rkat 43.267 and pKAT1.gag/pol.ATG encoding the functions required for the packaging of retroviral transcripts were kindly provided by Dr. Tom Dull (Cell Genesys, Foster City, Calif) and have been described previously. 4 pCMV VSV-G (strain Indiana) and the encephalomyocarditis virus internal ribosome entry site (IRES) used to express the neo R gene were obtained from Dr. Paul Robbins (University of Pittsburgh). phEGFPc-1 containing the hEGFP gene was purchased from Clontech (Heidelberg, Germany). The WT and no. 30 mutant HSV-1 TK genes (designated HSV-TK WT and HSV-TK 30 , respectively) were contained in pET23d vectors and kindly provided by Dr. Margaret Black (Darwin Molecular Corporation, Bothell, Wash). Plasmid DNA for subcloning and transfections was obtained by transforming religated plasmids or supercoiled DNA into Escherichia coli strain TOP10FЈ One Shot competent cells (Invitrogen, Leek, The Netherlands); next, plasmid DNA was purified from 100-mL overnight cultures using Qiagen Endofree plasmid isolation kits (Qiagen, Hilden, Germany).
Transfection of established cell lines and generation of transient VSV-G-pseudotyped retroviral supernatants
At 24 hours before transfection, 1 ϫ 10 6 293T cells were seeded into Primaria plates (Falcon no. 3803; Becton-Dickinson, Heidelburg, Germany). A total of 10 g of each retroviral plasmid vector (either rkat EGFP/neo, rkat TK WT /neo, or rkat TK 30 /neo), 7 g of the packaging plasmid pKAT 1.gag/pol. ATG, and 7 g of pCMV-VSV-G were then cotransfected into 293T cells using calcium phosphate coprecipitation. 38 Fresh medium was added on the following day, and viral supernatants were harvested 24 and 48 hours later, filtered through 0.45-mm low protein binding Acrodisc filters (no. 4184; Gelman Sciences, Ann Arbor, Mich), and stored at Ϫ80°C.
Generation of retroviral producer cell lines and virus titration
Aliquots of each respective transient vector supernatant (with a titer of 1 ϫ 10 6 colony-forming units (cfu)/mL) were used to infect 1 ϫ 10 5 FLYA13, FLYRD18, or 293 GPG cells seeded into 6-cm 2 dishes containing complete medium with 8 g/mL polybrene (Sigma, Deisenhoffen, Germany). After 48 hours, the transduced FLYA13 and FLYRD18 cells were placed in complete medium containing 700 g/mL G418 (Life Technologies). After 2 weeks, G418-resistant nonclonal pools were used to generate stocks of viral supernatants that were filtered through 0.45-mm low protein binding Acrodisc filters before storage at Ϫ20°C. Viral titrations were performed by infecting NIH 3T3 or HT1080 cells (pretreated with 8 g/mL polybrene) with serial dilutions of either the different viral stocks produced by the various FLYA13, FLYRD18, or 293 GPG producer cell lines or stocks produced by transient transfections in 293T cells. Infections were performed over a 24-hour period in 6-well plates, and the medium containing 800 g/mL G418 was added subsequently. After 12-14 days, resistant colonies were counted.
Transduction and analysis of transduced human pancreatic tumor cell lines
A total of 1 ϫ 10 5 Panc89, PancTuI, or Colo357 cells were seeded into 6-cm 2 dishes containing complete medium and 8 g/mL polybrene. After 24 hours, rkat EGFP/neo retroviral supernatants generated from either FLYA13, FLYRD18, or 293 GPG producer cell lines (equalized for titer) were used to infect these pancreatic cell lines at a multiplicity of infection of 10. The medium was replaced 24 hours later. To analyze the efficiency of transduction and short-term gene expression, the transduced cells were harvested with trypsin-ethylenediaminetetraacetic acid (EDTA) (Life Technologies), washed twice with 1ϫ phosphatebuffered saline, fixed in 2% formaldehyde, and analyzed for gene expression using a FACScalibur (Becton Dickinson). For longer term evaluation of gene expression and provector copy analysis, the remaining rkat hEGFP/neo-transduced pancreatic tumor cell lines were selected in G418 for 2 weeks using 700 g/mL. Genomic DNA was isolated from 1 ϫ 10 6 cells of each respective cell line using the Blood Midi Kit (Qiagen). For dot blot analysis, undigested DNA was diluted 1/5 and 1/25 and transferred to a Hybond nylon membrane (Amersham-Buchler, Braunschweig, Germany) using the SRC 96D Minifold I Dot Blotter (Schleicher & Schuell, Dassel, Germany). Genomic DNA was digested with EcoRI and BamHI and separated on a 0.8% tris(hydroxymethyl)-aminomethane acetate/EDTA agarose gel. For Southern blot analysis, digested DNA was transferred to a Hybond nylon membrane using Standard southern blotting procedures. 39 A purified 0.9-kb EcoRI-BamHI fragment coding for the hEGFP gene was labeled with [␣-32 P]cytidine triphosphate using the Redi-Prime Kit (Amersham-Buchler). Hybridization of the radiolabeled probe to the DNA contained on the nylon membranes was performed using Quick-Hyb solution (Stratagene, Amsterdam, Netherlands). After hybridization for 1 hour, the blots were washed twice at room temperature using 2ϫ standard saline phosphate/EDTA and 0.2% sodium dodecyl sulfate followed by two stringent washes using 0.1ϫ standard saline phosphate/ EDTA and 0.1% sodium dodecyl sulfate at 60°C. The blots were placed on film for several days before exposure. The values for radioactive signal strength were measured using the BAS 1000 Phosphorimager (Fuji Photo Film, Tokyo, Japan).
In vitro cytotoxicity assays
A total of 1 ϫ 10 4 pseudotyped rkat TK WT /neo-or rkat TK 30 /neo-transduced pancreatic tumor cells alone or mixed with unmodified cells in a 100-L volume were seeded into each well of a 96-well plate. After 24 hours, various concentrations of GCV (Cymevene; Syntex Pharmaceuticals, Aachen, Germany) were added in volumes of 100 L to each well. After 5 days, cytotoxicity was measured using the EZ4U cytotoxicity kit (Bio-Rad Laboratories, Munich, Germany) according to the manufacturer's instructions. After addition of the chromagenic substrate, the plates were scanned in an enzyme-linked immunosorbent assay reader (Anthos, Salzburg, Austria) at a 492-nm wavelength. The values were determined as a percentage of the value for control wells with no GCV added (n ϭ 6 for each GCV concentration).
Antitumoral efficacy between HSV-TK 30 /neo-transduced cells. At 5 days after palpable tumors had formed, daily intraperitoneal injections of 62.5 mg/kg GCV in 0.5 mL of sterile water for injection were given. Tumor growth was monitored every 5 days and measured in three dimensions using Vernier calipers; the volume of each tumor was calculated using the formula of a rotational ellipsoid (V ϭ l ϫ h ϫ w ϫ 0.5236). Each group contained seven mice that were kept in a laminar-airflow cabinet (Scanbur, Koge, Denmark) and given sterilized food and water ad libitum.
RESULTS
Retroviral constructs
We constructed a retroviral vector containing either the hEGFP gene, HSV-TK WT or HSV-TK 30 , and an IRES neo R cassette in the rkat MLV-backbone vector (Fig 1) , which has been modified to generate reasonably hightiter supernatants (ϳ1 ϫ 10 6 cfu/mL) in 293T cells by transient cotransfection of the vector backbone plasmid with plasmids coding for packaging functions (e.g., gag, pol, and an envelope). 4 Transduction of human pancreatic tumor cell lines For transduction of the Panc89, PancTuI, and Colo357 cell lines, we used either rkat hEGFP/neo, rkat TK WT / neo, or rkat TK 30 /neo vectors generated in three different packaging cell lines (FLYA13, FLYRD18, or 293 GPG). After generating the respective stable producer lines, supernatants were collected and the titer was determined for each type of retroviral vector. Before their use for infecting the target cell lines, the titer of each vector supernatant (FLYA13, 1.4 ϫ 10 7 cfu/mL; FLYRD18, 8.6 ϫ 10 6 cfu/mL; 293GPG, 4.6 ϫ 10 7 cfu/mL) was equalized to 1 ϫ 10 6 cfu/mL. We tested the ability of the rkat hEGFP/neo vector pseudotypes to infect pancreatic tumor lines. At 48 and 96 hours after infection with the various hEGFP vector pseudotypes, samples of each transduced cell line were analyzed for hEGFP expression using a fluorescence-activated cell sorter (FACS). (Fig 3) . Therefore, only minimal levels of pseudotransduction were observed in Panc89 cells transduced with VSV-G rkat hEGFP/neo vector. The data clearly indicate that VSV-Gpseudotyped retroviral vectors infected greater percentages of human pancreatic tumor cell lines and produced stronger gene expression than did RD114 or 4070A pseudotypes, with 4070A being the least efficient.
Pancreatic cells transduced with VSV-G hEGFP/neo pseudotypes possess more gene copies than RD114-or 4070A-transduced cells One of the issues with gene-modified cells is the lack of transgene expression. We have observed that expression of hEGFP remains high for as long as 3 months in culture. In contrast, the expression of hEGFP in RD114-or 4070A-pseudotyped rkat hEGFP/neo-transduced cells gradually weakens over the course of several months (data not shown). A possible reason for this difference in long-term gene expression may be related to the number of gene copies contained within the transduced cells. To address this question, we isolated genomic DNA from transduced cells selected for 2 weeks in G418. A total of 10 g of DNA from each (Table 1) . Gene copy number analysis in Colo357 cells transduced with VSV-G, RD114, or 4070A pseudotypes was similar to the respective pseudotyped-transduced Panc89 cells. Pancreatic cells transduced with RD 114-pseudotyped retroviral vectors showed gene copy numbers that were similar to those seen for 4070A-pseudotyped cells (data not shown).
VSV-G-pseudotyped rkat HSV-TK/neo-transduced
human pancreatic cell lines demonstrate higher sensitivity to GCV and more potent bystander effects in vitro After demonstrating that VSV-G-pseudotyped vectors show an enhanced ability to infect and amplify gene expression in human pancreatic tumor cell lines, we were interested in determining whether the presence of a higher gene copy number affected the sensitivity to GCV and the bystander effect in cells transduced with retroviral vectors containing either the HSV-TK WT Cytotoxicity and bystander data for Panc89 and PancTuI. GCV sensitivity was increased by 5-to 10-fold using VSV-G-pseudotyped retroviral vectors expressing the HSV-TK gene compared with pseudotyping with 4070A. Another 5-to 10-fold decrease in the LD 50 could be achieved using rkat TK 30 Table 2 shows the results of the bystander effect in Panc89 and PancTuI using a GCV concentration of 10 M, which corresponds to the maximal tolerable dose in mice. To determine the efficiency of the bystander effect, we mixed the various HSV-TK-transduced cells with untransduced cells in different ratios and measured the percentage of HSV-TK-positive cells in the cell mixture required to achieve 50% total cell killing. In addition, the percentage of survival using 20% HSV-TK-positive cells was determined, because this corresponds to the reported in vivo transduction efficiencies. 40 /neo VSV-G-and 4070A-pseudotyped retroviral vectors. Cells transduced with hEGFP were used as a control. The cytotoxic effect of GCV was determined using an EZ4U kit. After addition of the chromagenic substrate, the plates were scanned in an enzyme-linked immunosorbent assay reader (Anthos) at a 492-nm wavelength. The values are expressed as a percentage of the value for control wells with no GCV added (n ϭ 6 for each GCV concentration). The dotted line represents the LD 50 of the cells. cells was only observed using a GCV concentration of 100 M (data not shown).
PancTuITK
30 cells demonstrated higher sensitivity to GCV and generated a more potent bystander effect in vivo than PancTuITK WT cells
After demonstrating that VSV-G-pseudotyped rkat TK retroviral vectors increased both the sensitivity to GCV and the corresponding bystander effect in HSV-TKtransduced human pancreatic cell lines in vitro, and that sensitivity to GCV and the bystander effect were further augmented in human pancreatic cells after transduction with rkat retroviral vectors containing the HSV-TK (Fig 7B) demonstrated that after an initial increase in tumor volume, a reduction in tumor volume was followed by an increase in tumor regrowth, with the mice inoculated with 20% PancTuITK 30 -positive cells showing the stronger reduction and the slower regrowth.
DISCUSSION
A promising approach in gene therapy of cancer is to introduce the HSV-TK gene to pancreatic tumor cells in which HSV-TK monophosphorylates the prodrug GCV, along with other cellular kinases, into a toxic metabolite that inhibits DNA synthesis. 29 Several current clinical trials with the HSV-TK prodrug/GCV system use MLV-A (4070A) retroviral vectors containing the HSV-TK WT gene and have met with limited success. 14 To achieve an optimal therapeutic outcome, delivery of the HSV-TK gene to the highest number of cells in the targeted tumor as well as generation of potent bystander effects are critical requirements. In an effort to improve the ability of retroviral vectors to infect and generate better therapeutic gene expression in target tumor cell populations, we compared the ability of recombinant retroviruses bearing envelopes of either MLV 4070A, CEV RD114, or the rhabdovirus VSV-G to infect human pancreatic tumor cell lines and to affect subsequent gene expression in transduced cells. By identifying which of the known glycoprotein envelopes used for pseudotyping recombinant retroviral vectors mediates the maximal transduction in these cell types, we engineered retroviruses containing the genes for either HSV-TK WT or HSV-TK 30 (with increased affinity for phosphorylating GCV) and looked for differences in sensitivities toward GCV and the generation of a bystander effect in mixed populations of transduced and untransduced human pancreatic tumor cell lines.
In evaluating the capability of different viral envelope glycoproteins to mediate infectivity, we used a retroviral vector containing the hEGFP gene pseudotyped with either MLV 4070A, CEV RD114, or rhabdovirus VSV-G glycoprotein envelopes to infect several pancreatic tumor cell lines. We found that at 48 hours postinfection, there were four to five times more fluorescent cells in VSV-G-rkat hEGFP/neo vector-transduced populations compared with cells transduced with either RD114-or 4070A-pseudotyped rkat hEGFP/neo virions. Although the levels of fluorescence increased in all pseudotyped populations by 96 hours, the level of fluorescence was still 2-fold higher in VSV-G rkat hEGFP/ neo-transduced cells and the median fluorescence intensity was still 5-to 10-fold higher. Because the level of transduction was very similar in RD114 and 4070A rkat hEGFP/neo-infected cell populations, we concentrated on differences between infection using VSV-G or 4070A pseudotypes. It has been reported that using concentrated VSV-G pseudotyped virions generated false positives in target cells due to passive antigen transfer or pseudotranduction. 41 To address this issue, we isolated genomic DNA from G418-selected cells transduced with either VSV-G-or 4070A-pseudotyped rkat hEGFP/neo vectors. Dot blot analysis determined that cells transduced with VSV-G rkat hEGFP/neo pseudotype con- There is a lack of data describing the comparative transducibility of retroviral vectors in human pancreatic cell lines. In addition, the cell lines we used to analyze the transducibility of human pancreatic tumor cells may represent a minor fraction of the cells within a pancreatic tumor mass. However, retroviral transduction studies on other types of human cells reveal that certain glycoprotein envelopes mediate higher efficiencies for infecting particular cell types (e.g., VSV-G for human peripheral blood lymphocytes, 41 gibbon ape leukemia virus for human cord blood progenitors, 42 and MLV 4070A for primary human melanoma). 43 It may be appropriate to pretest the transducibility of additional cell lines for a particular cancer using several retroviral vector pseudotypes, to identify the most suitable envelope that mediates superior infection and gene expression, and to adapt the gene therapy to the clinical target.
Next, we determined whether the enhanced infectivity and gene expression using VSV-G pseudotypes could be used to generate higher sensitivities and more potent bystander effects in human pancreatic cell lines transduced with retroviral vectors containing HSV-TK genes. The most dramatic differences in sensitivities to GCV were seen between Panc89 and PancTuI cells transduced with the VSV-G rkat TK 30 One explanation for the higher sensitivity to GCV in VSV-G pseudotype-transduced cells may be the presence of higher levels of HSV-TK (due to higher gene copy number), leading to the generation of greater levels of GCV-triphosphate that can be transferred between cells, leading to more overall cell killing. If one can assume that a 20% rate of transduction is the maximum achieved by current recombinant retroviral infection protocols, then the bystander effect is an essential component for the successful application of suicide gene cancer therapy. The differences between Panc89 and PancTuI cells transduced with VSV-G rkat TK 30 /neo retrovirus or 4070A rkat TK WT /neo retrovirus demonstrated that fewer cells needed to be "gene modified" to achieve greater bystander killing of unmodified cells. Figure 6A shows that a mixture of 20% Panc89 cells transduced with VSV-G rkat TK 30 /neo retrovirus can achieve the same level of killing as 100% Panc89 cells transduced with 4070A/HSV-TK WT /neo retrovirus when GCV is used at 10 mol. More than 85% of the total cells were killed. Although the level of bystander killing is not as extensive, as shown in Figure 6B , a mixture of 20% PancTuI cells transduced with VSV-G rkat TK 30 / neo retrovirus also achieves a better level of killing than 100% PancTuI transduced with 4070A rkat TK WT /neo retrovirus, where the level of killing reaching only 60%. The difference between the levels of connexin expression (and general levels of functional gap junctions) found on Panc89 and PancTuI needed for the transfer of GCVtriphosphate to adjacent cells may account for the variation in bystander effects. 34 To support our findings in an in vivo setting, we focused on the two HSV-TK genes and compared the sensitivity to GCV of HSV-TK WT -and HSV-TK 30 In addition to identifying the most suitable envelope for transducing human pancreatic tumor cells, the next step is to determine tissue-specific promoters or transcriptional control elements, which may limit the expression of the HSV-TK gene to pancreatic tumor cells. 45 A number of these elements have been evaluated for use in pancreatic cell lines. In this report, we used a retroviral vector containing the hEGFP gene to demonstrate that retroviral vectors pseudotyped with VSV-G glycoproteins provided the best transduction efficiency for human pancreatic tumor cells compared with either MLV 4070A-or CEV RD114-pseudotyped retroviral vectors. The higher gene expression found in pancreatic cells transduced with VSV-G-pseudotyped retroviral vectors was due to the presence of a higher number of EGFP genes as determined by dot blot analysis. Even after G418 selection and extended growth in vitro, the expression of EGFP was consistently higher in VSV-G-infected cells compared with cells infected with either 4070A-or RD114-pseudotyped retroviral vectors. It is likely that the additional HSV-TK and higher affinity mutant HSV-TK generated by transduction with VSV-Gpseudotyped rkat TK WT /neo and rkat TK 30 /neo retroviruses produced greater quantities of GCV-triphosphate, which enhanced the level of bystander killing in adjacent cells connected via gap junctions. Data from the studies conducted in BALB/c-SCID mice inoculated with PancTuITK 30 clearly demonstrate the superiority of the HSV-TK 30 gene in the elimination of TK-positive cells in vivo. This study suggests that the use of VSV-G glycoprotein for the pseudotyping of recombinant retroviruses enhances the delivery and expression of the hEGFP and HSV-TK genes in human pancreatic tumor cell lines and may be an important feature in vector design for the gene therapy of pancreatic cancer.
